Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH003 with Toripalimab in Advanced Solid Tumors
NCT04481009Phase 2Completed
- Sponsor
- Eucure Biopharma
- Start
- Aug 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ciltistotug in solid tumor (advanced stage), melanoma, pancreatic ductal adenocarcinoma (PDAC), sponsored by Eucure Biopharma. Started Aug 2020; status: completed.
02
Drugs
ciltistotug
03
Conditions
solid tumor (advanced stage)melanomapancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04481009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481009.